WELCOME TO
KAIROS PHARMA
Therapeutics to reverse cancer drug resistance and immune suppression
WELCOME TO
KAIROS PHARMA
Therapeutics to reverse cancer drug resistance and immune suppression
About us
Kairos Pharma is a clinical-stage biopharmaceutical company that has developed novel therapies to reverse the resistance that develops to cancer drugs and to reverse immune suppression caused by cancer.
The word "Kairos" means "the opportune moment to intervene." Our therapies are designed to act at that critical point—when cancer drug resistance or immune suppression threatens a patient’s treatment.
Reversing cancer drug resistance
Our lead drug, ENV105 targets the protein CD105 which we identified as a cause for resistance to many types of cancer therapies. Our antibody, ENV105, reverses drug resistance caused by CD105 on the surface of cancer cells. ENV105 is currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer. As the CD105 mechanism appears to drive many forms of cancer drug resistance, ENV105 has the potential to address resistance in a wide range of cancers as they become resistant to standard treatments.
Advancing
Immunotherapy
Kairos Pharma has developed novel T cell therapies to increase the number of T cells that can attack cancer cells and enhance their cytotoxicity making them “meaner”. KROS101 is a small molecule that may be the only known immunotherapy capable of both expanding T cell populations and making them more effective at killing cancer cells.
KROS201 has cleared an Investigational New Drug (IND) application with the FDA to begin clinical trials. This therapy infuses autologous T cells to target and destroy cancer stem cells, which are believed to be the root cause of glioblastoma.
Addressing key mechanisms of cancer drug resistance and immune suppression
New technologies developed through structural biology to reverse key mechanisms of cancer drug resistance and immune suppression. Transforming the way cancer is treated.
About us
Kairos Pharma is a clinical-stage biopharmaceutical company that has developed novel therapies to reverse the resistance that develops to cancer drugs and to reverse immune suppression caused by cancer.
The word "Kairos" means "the opportune moment to intervene." Our therapies are designed to act at that critical point—when cancer drug resistance or immune suppression threatens a patient’s treatment.
Reversing cancer drug resistance
Our lead drug, ENV105 targets the protein CD105 which we identified as a cause for resistance to many types of cancer therapies. Our antibody, ENV105, reverses drug resistance caused by CD105 on the surface of cancer cells. ENV105 is currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer. As the CD105 mechanism appears to drive many forms of cancer drug resistance, ENV105 has the potential to address resistance in a wide range of cancers as they become resistant to standard treatments.
Advancing Immunotherapy
Kairos Pharma is developing small molecules that target central “checkpoints” of the immune response to cancer. In addition, Kairos is developing an activated T cell therapy that transforms a patient’s T cells into killer activated T cells against the stem cells that drive the patient’s cancer.
Addressing key mechanisms of cancer drug resistance and immune suppression.
New technologies developed through structural biology to reverse key mechanisms of cancer drug resistance and immune suppression. Transforming the way cancer is treated.
